Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma

Christine P. Hans, Dennis D. Weisenburger, Timothy Charles Greiner, Wing C. Chan, Patricia Aoun, Gregory T. Cochran, Zenggang Pan, Lynette M Smith, James C. Lynch, Robert G Bociek, Philip Jay Bierman, Julie Marie Vose, James Olen Armitage

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

We sought to determine whether identification of poor-risk subgroups of diffuse large B-cell lymphoma (DLBCL) using immunohistochemical stains would have practical utility with regard to prognosis and therapeutic decisions. Tissue microarray blocks were created using replicate samples of formalin-fixed, paraffin-embedded tissue from 200 cases of de novo DLBCL. The sections were stained with antibodies to proteins that are expressed by activated or proliferating B cells including MUM1, FOXP1, bcl-2, survivin, protein kinase C-beta (PKC-β), cyclin D2, cyclin D3, and Ki-67. In univariate analysis, tumor expression of cyclin D2 (P=0.025) or PKC-β (P=0.015) was associated with a worse overall survival, whereas none of the other markers was predictive of overall survival. Patients with DLBCL that expressed either cyclin D2 or PKC-β had a 5-year overall survival of only 30% as compared to 52% for those who were negative for both markers (P=0.0019). In multivariate analysis, the expression of cyclin D2 or PKC-β was an independent predictor of poor overall survival (P=0.035). Cyclin D2 and PKC-β expression will be useful in designing a 'biological prognostic index' for patients with DLBCL.

Original languageEnglish (US)
Pages (from-to)1377-1384
Number of pages8
JournalModern Pathology
Volume18
Issue number10
DOIs
StatePublished - Oct 1 2005

Fingerprint

Cyclin D2
Protein Kinase C beta
Lymphoma, Large B-Cell, Diffuse
Survival
Cyclin D3
Paraffin
Formaldehyde
B-Lymphocytes
Coloring Agents
Multivariate Analysis
Antibodies
Neoplasms
Proteins

Keywords

  • Cyclin D2
  • Diffuse large B-cell lymphoma
  • Immunohistochemistry
  • Protein kinase C-beta

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. / Hans, Christine P.; Weisenburger, Dennis D.; Greiner, Timothy Charles; Chan, Wing C.; Aoun, Patricia; Cochran, Gregory T.; Pan, Zenggang; Smith, Lynette M; Lynch, James C.; Bociek, Robert G; Bierman, Philip Jay; Vose, Julie Marie; Armitage, James Olen.

In: Modern Pathology, Vol. 18, No. 10, 01.10.2005, p. 1377-1384.

Research output: Contribution to journalArticle

Hans, Christine P. ; Weisenburger, Dennis D. ; Greiner, Timothy Charles ; Chan, Wing C. ; Aoun, Patricia ; Cochran, Gregory T. ; Pan, Zenggang ; Smith, Lynette M ; Lynch, James C. ; Bociek, Robert G ; Bierman, Philip Jay ; Vose, Julie Marie ; Armitage, James Olen. / Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. In: Modern Pathology. 2005 ; Vol. 18, No. 10. pp. 1377-1384.
@article{c1e914e415004df4aa6799c0ed7156c6,
title = "Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma",
abstract = "We sought to determine whether identification of poor-risk subgroups of diffuse large B-cell lymphoma (DLBCL) using immunohistochemical stains would have practical utility with regard to prognosis and therapeutic decisions. Tissue microarray blocks were created using replicate samples of formalin-fixed, paraffin-embedded tissue from 200 cases of de novo DLBCL. The sections were stained with antibodies to proteins that are expressed by activated or proliferating B cells including MUM1, FOXP1, bcl-2, survivin, protein kinase C-beta (PKC-β), cyclin D2, cyclin D3, and Ki-67. In univariate analysis, tumor expression of cyclin D2 (P=0.025) or PKC-β (P=0.015) was associated with a worse overall survival, whereas none of the other markers was predictive of overall survival. Patients with DLBCL that expressed either cyclin D2 or PKC-β had a 5-year overall survival of only 30{\%} as compared to 52{\%} for those who were negative for both markers (P=0.0019). In multivariate analysis, the expression of cyclin D2 or PKC-β was an independent predictor of poor overall survival (P=0.035). Cyclin D2 and PKC-β expression will be useful in designing a 'biological prognostic index' for patients with DLBCL.",
keywords = "Cyclin D2, Diffuse large B-cell lymphoma, Immunohistochemistry, Protein kinase C-beta",
author = "Hans, {Christine P.} and Weisenburger, {Dennis D.} and Greiner, {Timothy Charles} and Chan, {Wing C.} and Patricia Aoun and Cochran, {Gregory T.} and Zenggang Pan and Smith, {Lynette M} and Lynch, {James C.} and Bociek, {Robert G} and Bierman, {Philip Jay} and Vose, {Julie Marie} and Armitage, {James Olen}",
year = "2005",
month = "10",
day = "1",
doi = "10.1038/modpathol.3800434",
language = "English (US)",
volume = "18",
pages = "1377--1384",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma

AU - Hans, Christine P.

AU - Weisenburger, Dennis D.

AU - Greiner, Timothy Charles

AU - Chan, Wing C.

AU - Aoun, Patricia

AU - Cochran, Gregory T.

AU - Pan, Zenggang

AU - Smith, Lynette M

AU - Lynch, James C.

AU - Bociek, Robert G

AU - Bierman, Philip Jay

AU - Vose, Julie Marie

AU - Armitage, James Olen

PY - 2005/10/1

Y1 - 2005/10/1

N2 - We sought to determine whether identification of poor-risk subgroups of diffuse large B-cell lymphoma (DLBCL) using immunohistochemical stains would have practical utility with regard to prognosis and therapeutic decisions. Tissue microarray blocks were created using replicate samples of formalin-fixed, paraffin-embedded tissue from 200 cases of de novo DLBCL. The sections were stained with antibodies to proteins that are expressed by activated or proliferating B cells including MUM1, FOXP1, bcl-2, survivin, protein kinase C-beta (PKC-β), cyclin D2, cyclin D3, and Ki-67. In univariate analysis, tumor expression of cyclin D2 (P=0.025) or PKC-β (P=0.015) was associated with a worse overall survival, whereas none of the other markers was predictive of overall survival. Patients with DLBCL that expressed either cyclin D2 or PKC-β had a 5-year overall survival of only 30% as compared to 52% for those who were negative for both markers (P=0.0019). In multivariate analysis, the expression of cyclin D2 or PKC-β was an independent predictor of poor overall survival (P=0.035). Cyclin D2 and PKC-β expression will be useful in designing a 'biological prognostic index' for patients with DLBCL.

AB - We sought to determine whether identification of poor-risk subgroups of diffuse large B-cell lymphoma (DLBCL) using immunohistochemical stains would have practical utility with regard to prognosis and therapeutic decisions. Tissue microarray blocks were created using replicate samples of formalin-fixed, paraffin-embedded tissue from 200 cases of de novo DLBCL. The sections were stained with antibodies to proteins that are expressed by activated or proliferating B cells including MUM1, FOXP1, bcl-2, survivin, protein kinase C-beta (PKC-β), cyclin D2, cyclin D3, and Ki-67. In univariate analysis, tumor expression of cyclin D2 (P=0.025) or PKC-β (P=0.015) was associated with a worse overall survival, whereas none of the other markers was predictive of overall survival. Patients with DLBCL that expressed either cyclin D2 or PKC-β had a 5-year overall survival of only 30% as compared to 52% for those who were negative for both markers (P=0.0019). In multivariate analysis, the expression of cyclin D2 or PKC-β was an independent predictor of poor overall survival (P=0.035). Cyclin D2 and PKC-β expression will be useful in designing a 'biological prognostic index' for patients with DLBCL.

KW - Cyclin D2

KW - Diffuse large B-cell lymphoma

KW - Immunohistochemistry

KW - Protein kinase C-beta

UR - http://www.scopus.com/inward/record.url?scp=25144466151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144466151&partnerID=8YFLogxK

U2 - 10.1038/modpathol.3800434

DO - 10.1038/modpathol.3800434

M3 - Article

C2 - 15920548

AN - SCOPUS:25144466151

VL - 18

SP - 1377

EP - 1384

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 10

ER -